Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lafutidine for prevention of paclitaxel-induced peripheral neuropathy in non-small cell lung cancer
jRCTs021200031Completed
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of lafutidine in chemotherapy-induced peripheral neuropathy (CIPN) (2 arms). Primary endpoint: Grade 2 or higher peripheral neuropathy. Started Jan 2021; status: completed.
02
Drugs
lafutidine
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on jRCTs021200031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021200031.